U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma

MedGen UID:
1667050
•Concept ID:
C4727781
•
Neoplastic Process
Synonym: Locally Advanced Non-Squamous Non-Small Cell Lung Carcinoma

Definition

Non-squamous non-small cell lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLocally Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Professional guidelines

PubMed

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials.
Daei Sorkhabi A, ZareDini M, Fazlollahi A, Sarkesh A, Naseri A, Mousavi SE, Nejadghaderi SA, Sullman MJM, Kolahi AA, Safiri S
BMC Pulm Med 2023 Dec 8;23(1):495. doi: 10.1186/s12890-023-02755-3. PMID: 38066549Free PMC Article
The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer.
Manzo A, Carillio G, Montanino A, Sforza V, Palumbo G, Esposito G, Costanzo R, Sandomenico C, La Manna C, Martucci N, La Rocca A, De Luca G, Piccirillo MC, De Cecio R, Botti G, Totaro G, Muto P, Picone C, Normanno N, Morabito A
Expert Opin Drug Saf 2020 Jul;19(7):775-783. Epub 2020 May 26 doi: 10.1080/14740338.2020.1767584. PMID: 32400223
New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.
Cameron L, Solomon B
Curr Treat Options Oncol 2015 Oct;16(10):49. doi: 10.1007/s11864-015-0367-z. PMID: 26318457

Recent clinical studies

Etiology

STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Oudart JB, Garinet S, Leger C, Barlesi F, Mazières J, Jeannin G, Audigier-Valette C, Morot-Sibilot D, Langlais A, Amour E, Mathiot N, Birsen G, Blons H, Wislez M
Lung Cancer 2024 Apr;190:107508. Epub 2024 Feb 19 doi: 10.1016/j.lungcan.2024.107508. PMID: 38428265
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S, Wu L, Jian H, Cheng Y, Wang Q, Fang J, Wang Z, Hu Y, Han L, Sun M, Miao L, Ding C, Cui J, Wang K, Li B, Li X, Ye F, Liu A, Pan Y, Cang S, Zhou H, Sun X, Shen Y, Wang S, Zhang W, He Y
Lancet Respir Med 2023 Jul;11(7):624-636. Epub 2023 May 5 doi: 10.1016/S2213-2600(23)00135-2. PMID: 37156249
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C
Lancet Oncol 2022 Sep;23(9):1167-1179. Epub 2022 Jul 28 doi: 10.1016/S1470-2045(22)00382-5. PMID: 35908558
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators
Lancet 2019 May 4;393(10183):1819-1830. Epub 2019 Apr 4 doi: 10.1016/S0140-6736(18)32409-7. PMID: 30955977

Diagnosis

The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
Liu S, Graves N, Tan AC
Lung Cancer 2024 May;191:107794. Epub 2024 Apr 15 doi: 10.1016/j.lungcan.2024.107794. PMID: 38636314
Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
Li F, Chen Y, Xiao D, Jiang S, Yang Y
Adv Ther 2024 Apr;41(4):1436-1449. Epub 2024 Feb 15 doi: 10.1007/s12325-024-02808-x. PMID: 38356107
Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L, Qian Y, Li J, Cui C, Chen L, Qu S, Lu S
Future Oncol 2022 May;18(15):1896-1905. Epub 2022 Mar 21 doi: 10.2217/fon-2021-1336. PMID: 35311347
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Extending survival of stage IV non-small cell lung cancer.
Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV
Semin Oncol 2014 Feb;41(1):69-92. Epub 2013 Dec 21 doi: 10.1053/j.seminoncol.2013.12.013. PMID: 24565582

Therapy

Ivonescimab: First Approval.
Dhillon S
Drugs 2024 Sep;84(9):1135-1142. Epub 2024 Jul 29 doi: 10.1007/s40265-024-02073-w. PMID: 39073550
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S, Wu L, Jian H, Cheng Y, Wang Q, Fang J, Wang Z, Hu Y, Han L, Sun M, Miao L, Ding C, Cui J, Wang K, Li B, Li X, Ye F, Liu A, Pan Y, Cang S, Zhou H, Sun X, Shen Y, Wang S, Zhang W, He Y
Lancet Respir Med 2023 Jul;11(7):624-636. Epub 2023 May 5 doi: 10.1016/S2213-2600(23)00135-2. PMID: 37156249
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C
Lancet Oncol 2022 Sep;23(9):1167-1179. Epub 2022 Jul 28 doi: 10.1016/S1470-2045(22)00382-5. PMID: 35908558
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.
Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, Li W, Cui J, Wang D, Liao W, Zhou J, Wang Z, Sun Y, Qiu X, Gao J, Bao Y, Liang L, Wang M
J Thorac Oncol 2021 Sep;16(9):1512-1522. Epub 2021 May 23 doi: 10.1016/j.jtho.2021.05.005. PMID: 34033975
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators
Lancet 2019 May 4;393(10183):1819-1830. Epub 2019 Apr 4 doi: 10.1016/S0140-6736(18)32409-7. PMID: 30955977

Prognosis

STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Oudart JB, Garinet S, Leger C, Barlesi F, Mazières J, Jeannin G, Audigier-Valette C, Morot-Sibilot D, Langlais A, Amour E, Mathiot N, Birsen G, Blons H, Wislez M
Lung Cancer 2024 Apr;190:107508. Epub 2024 Feb 19 doi: 10.1016/j.lungcan.2024.107508. PMID: 38428265
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.
Trédaniel J, Barlési F, Le Péchoux C, Lerouge D, Pichon É, Le Moulec S, Moreau L, Friard S, Westeel V, Petit L, Carré O, Guichard F, Raffy O, Villa J, Prévost A, Langlais A, Morin F, Wislez M, Giraud P, Zalcman G, Mornex F; French Cooperative Thoracic Intergroup (IFCT)
Cancer Radiother 2022 Sep;26(5):670-677. Epub 2022 Mar 5 doi: 10.1016/j.canrad.2021.12.005. PMID: 35260342
Economic analyses of immune-checkpoint inhibitors to treat lung cancer.
Vergnenegre A, Chouaid C
Expert Rev Pharmacoecon Outcomes Res 2021 Jun;21(3):365-371. Epub 2020 Dec 24 doi: 10.1080/14737167.2021.1863790. PMID: 33306411
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K
Lung Cancer 2018 Aug;122:234-242. Epub 2018 May 24 doi: 10.1016/j.lungcan.2018.05.023. PMID: 30032838
Extending survival of stage IV non-small cell lung cancer.
Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV
Semin Oncol 2014 Feb;41(1):69-92. Epub 2013 Dec 21 doi: 10.1053/j.seminoncol.2013.12.013. PMID: 24565582

Clinical prediction guides

STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Oudart JB, Garinet S, Leger C, Barlesi F, Mazières J, Jeannin G, Audigier-Valette C, Morot-Sibilot D, Langlais A, Amour E, Mathiot N, Birsen G, Blons H, Wislez M
Lung Cancer 2024 Apr;190:107508. Epub 2024 Feb 19 doi: 10.1016/j.lungcan.2024.107508. PMID: 38428265
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J, Yu X, Huang D, Ma Z, Gao B, Cui J, Chu Q, Zhou Q, Sun M, Day D, Wu J, Pan H, Wang L, Voskoboynik M, Wang Z, Liu Y, Li H, Zhang J, Peng Y, Wu YL
J Immunother Cancer 2023 Feb;11(2) doi: 10.1136/jitc-2022-006055. PMID: 36808075Free PMC Article
Economic analyses of immune-checkpoint inhibitors to treat lung cancer.
Vergnenegre A, Chouaid C
Expert Rev Pharmacoecon Outcomes Res 2021 Jun;21(3):365-371. Epub 2020 Dec 24 doi: 10.1080/14737167.2021.1863790. PMID: 33306411
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators
Lancet 2019 May 4;393(10183):1819-1830. Epub 2019 Apr 4 doi: 10.1016/S0140-6736(18)32409-7. PMID: 30955977
Extending survival of stage IV non-small cell lung cancer.
Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV
Semin Oncol 2014 Feb;41(1):69-92. Epub 2013 Dec 21 doi: 10.1053/j.seminoncol.2013.12.013. PMID: 24565582

Recent systematic reviews

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials.
Daei Sorkhabi A, ZareDini M, Fazlollahi A, Sarkesh A, Naseri A, Mousavi SE, Nejadghaderi SA, Sullman MJM, Kolahi AA, Safiri S
BMC Pulm Med 2023 Dec 8;23(1):495. doi: 10.1186/s12890-023-02755-3. PMID: 38066549Free PMC Article
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA
Cochrane Database Syst Rev 2021 Mar 18;3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3. PMID: 33734432Free PMC Article
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA
Cochrane Database Syst Rev 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. PMID: 27223332
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R
Health Technol Assess 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. PMID: 23886301Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...